Current Report Filing (8-k)
May 30 2019 - 8:06AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
_____________________
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of report (date of earliest event reported): May 29, 2019
_____________________
TONIX
PHARMACEUTICALS HOLDING CORP.
(Exact
name of registrant as specified in its charter)
Nevada
|
001-36019
|
26-1434750
|
(State
or Other Jurisdiction
of
Incorporation)
|
(Commission
File
Number)
|
(IRS
Employer
Identification
No.)
|
509
Madison Avenue, Suite 1608, New York, New York 10022
(Address
of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code:
(212) 980-9155
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§
230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
Trading
Symbol(s)
|
Name
of each exchange on which registered
|
Common
Stock
|
TNXP
|
The
NASDAQ Global Market
|
|
Item
7.01
|
Regulation
FD Disclosure.
|
Tonix
Pharmaceuticals Holding Corp. (the “Company”) presented a poster (the “Poster Presentation”)
entitled “Steady-State Pharmacokinetic Properties of a Sublingual Formulation of Cyclobenzaprine (CBP) HCl (TNX-102
SL*): Comparison to Simulations of Oral Immediate Release CBP” on May 29, 2019 at the American Society of Clinical
Psychopharmacology (ASCP) 2019 Annual Meeting. Copies of the Poster Presentation and the press release that discusses
this matter are filed as Exhibits 99.01 and 99.02, respectively, to, and incorporated by reference in, this
report.
The
information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.01 and Exhibit 99.02 attached
hereto, shall not be deemed “filed” for purposes of Section 18 of the United States Securities Exchange Act of
1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the United States Securities Act of 1933 or the Exchange Act, except as shall be expressly set
forth by specific reference in such a filing.
Item
9.01
|
Financial
Statements and Exhibits.
|
(d)
|
|
Exhibit
No.
|
|
Description.
|
|
|
|
|
|
99.01
99.02
|
|
Poster
Presentation
Press
Release dated May 30, 2019, issued by the Company
|
SIGNATURE
Pursuant
to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
TONIX
PHARMACEUTICALS HOLDING CORP.
Date: May
30, 2019
|
By:
/s/ Bradley Saenger
|
|
Bradley
Saenger
|
|
Chief
Financial Officer
|
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Apr 2023 to Apr 2024